Navigation Links
Enterome In-licenses Novel Compounds From Vertex Pharmaceuticals to Treat Microbiome-related Inflammatory Bowel Diseases
Date:4/18/2016

PARIS and BOSTON, April 18, 2016 /PRNewswire/ --

First novel small molecule FimH antagonists to enter clinical development in 2016 

ENTEROME Bioscience SA, a pioneer in the development of pharmaceuticals and diagnostics based on the gut microbiome, has signed an exclusive worldwide license agreement with Vertex Pharmaceuticals Inc. (Nasdaq: VRTX) to research, develop and commercialize novel small molecule FimH antagonists for use in the treatment of inflammatory bowel diseases (IBD).

Enterome plans to take the lead compound in this program, known as EB 8018, into first human clinical trials during 2016 as well as a companion diagnostic to identify patients with inflammatory bowel diseases (IBD) who will benefit from their use.

Through application of its metagenomics platform, Enterome has identified a key bacterial species - adherent-invasive Escherichia coli (AIEC) - which is responsible for triggering inflammation in IBD. AIEC adheres to gut epithelial cells by virtue of FimH adhesion proteins on its cell surface, which bind to the CEACAM6 receptor on gut epithelial cells and allow the bacterial cells to invade the gut wall and proliferate. Research has shown that blocking FimH prevents the adherence and proliferation of AIEC, thereby reducing inflammation and providing new opportunities for the prevention and treatment of IBD.

"The rapid growth of evidence supporting the involvement of the microbiome in serious diseases is providing myriad new opportunities and targets for therapeutic intervention with small molecule drugs," commented Pierre Belichard, CEO of Enterome. "The unique insights we have gained on the roles of specific constituents of the gut microbiome brought through our metagenomics platform strongly supports the central role of AIEC in inflammatory bowel diseases. Through this in-licensing agreement we are delighted to gain access to these novel FimH antagonists including EB8018, which we intend to advance into clinical trials during 2016, and which we believe could be transformative for the management and treatment of IBD."

About Enterome 

Enterome is pioneering the development of novel pharmaceuticals and diagnostics to support personalized therapies in microbiome-related diseases such as Inflammatory Bowel Disease (IBD), cancer and metabolic diseases.

Enterome is also leading the development of new industry standards in gut microbiome quantitative and functional analysis. This technology leadership allows Enterome to open up the new field of therapeutic target discovery in the microbiome in order to address significant unmet medical needs.

Enterome has established partnerships with leading pharmaceutical companies and academic research institutes, including Johnson & Johnson Innovation/Janssen Biotech, Takeda and Abbvie in inflammatory bowel diseases; and the Mayo Clinic and Geisinger hospitals in metabolic disorders.

The Company was established in 2012 in Paris, France to develop the discoveries made by the INRA metagenomic platform. The Company has raised a total of €17.5 million from leading venture capital investors (Seventure Partners, Lundbeckfond Ventures & Omnes Capital) and two strategic investors (Shire & INRA transfer).

Additional information about Enterome is available through its website : http://www.enterome.com.

Contacts 
Pierre Belichard, CEO 
+33-1-75-77-27-87

David Dible / Mark Swallow / Marine Perrier, Citigate Dewe Rogerson 
+44-207-638-9571

enterome@citigatedr.co.uk

 



'/>"/>
SOURCE Enterome Bioscience SA
Copyright©2016 PR Newswire.
All rights reserved


Related medicine technology :

1. EnteroMedics to Host Second Quarter 2014 Financial Results and Business Update Conference Call
2. EnteroMedics to Participate in Canaccord Genuity 34th Annual Growth Conference
3. EnteroMedics Reports Second Quarter 2014 Financial Results
4. Health Care Equipment Equities under the Scanner - Medtronic, Abbott Laboratories, Stryker, Zeltiq Aesthetics, and EnteroMedics
5. Treatment of Type 2 Diabetes Mellitus added to EnteroMedics CE Mark for Obesity
6. EnteroMedics to Host Fourth Quarter 2014 Financial Results and Commercialization Update Conference Call
7. EnteroMedics Reports Fourth Quarter 2014 Financial Results
8. EnteroMedics to Present at Upcoming Investor Conferences
9. EnteroMedics Announces Partnership with American HealthCare Lending to Support Patient Access and Enhance Affordability of vBloc Therapy
10. EnteroMedics Announces Update on vBloc Therapy Trained Centers and Physicians
11. EnteroMedics Reports First Quarter 2015 Financial Results and Provides Business Update
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/12/2017)... 12, 2017 AVACEN Medical , Inc. (AVACEN) ... their  2017 New Product Innovation Award for Its fibromyalgia ... and secondary medical device market research by Frost & Sullivan,s ... OTC, drug-free pain relief product, the AVACEN 100, offers a ... fibromyalgia widespread pain. ...
(Date:10/11/2017)... 2017  Caris Life Sciences ® , a leading ... of precision medicine, today announced that St. Jude Medical ... Alliance™ (POA) as its 17 th member. Through ... Crosson Cancer Institute will help develop standards of care ... profiling, making cancer treatment more precise and effective. ...
(Date:10/10/2017)... --  West Pharmaceutical Services, Inc. (NYSE: WST), a ... today shared the results of a study highlighting the ... administration of polio vaccines. The study results were presented ... by Dr. Ondrej Mach , Clinical Trials and ... and recently published in the journal Vaccine. i ...
Breaking Medicine Technology:
(Date:10/12/2017)... (PRWEB) , ... October 12, 2017 , ... IsoComforter, Inc. ... products, announced today the introduction of an innovative new design of the shoulder pad. ... so you get maximum comfort while controlling your pain while using cold therapy. By ...
(Date:10/12/2017)... ... October 12, 2017 , ... Asante, a ... health care, have expanded their existing home health joint venture through an agreement, ... been operating a joint venture home health company with Asante, delivering clinically integrated ...
(Date:10/12/2017)... ... October 12, 2017 , ... Dr. Parsa Mohebi, the Los ... article to the newly revamped Cosmetic Town journal section, featuring articles ... procedure known as Follicular Unit Extraction (FUE). , Dr. Mohebi says ...
(Date:10/12/2017)... Washington, D.C. (PRWEB) , ... October 12, 2017 , ... ... of their peers in Washington, D.C., for the 49th Congress of the International ... Ph.D ., Vice President of the Center for Cancer and Blood Disorders ...
(Date:10/12/2017)... RAPIDS, Mich. (PRWEB) , ... October 12, 2017 ... ... Wellness, has been named one of Michigan’s 2017 Best and Brightest in Wellness® ... and Brightest in Wellness® awards program on Friday, Oct. 20 from 7:30 a.m. ...
Breaking Medicine News(10 mins):